Stocktoria
PAVmed Inc. PAVM
PAVmed Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71,000 | $3.0M | $2.5M | $377,000 | $500,000 | — | — | — | — | — |
| Gross profit | — | — | — | — | -$85,000 | — | — | — | — | — |
| R&D expense | $4.5M | $5.9M | $14.3M | $25.3M | $19.8M | $11.0M | $6.6M | $4.3M | $2.6M | $1.7M |
| Operating income | -$21.8M | -$44.5M | -$68.8M | -$91.1M | -$54.4M | -$23.4M | -$14.3M | -$10.6M | -$8.0M | -$5.7M |
| Interest expense | — | — | — | — | — | — | — | $2.4M | $724,684 | — |
| Income tax | $0 | $0 | — | — | — | — | — | — | — | — |
| Net income | $401,000 | $39.8M | -$64.2M | -$89.0M | -$50.3M | -$34.3M | -$16.5M | -$18.0M | -$9.5M | -$5.7M |
| EPS (diluted) | $-5.63 | $14.90 | $-9.16 | $-15.03 | — | — | — | — | — | — |
| Operating cash flow | -$5.2M | -$33.6M | -$52.0M | -$71.0M | -$40.6M | -$21.9M | -$13.4M | -$8.8M | -$6.6M | -$4.5M |
| Free cash flow | -$5.2M | -$33.6M | -$52.3M | -$72.5M | -$42.1M | -$22.0M | -$13.4M | -$8.8M | -$6.6M | -$4.5M |
| Cash & equivalents | $1.5M | $1.2M | $19.6M | $39.7M | $77.3M | $17.3M | $6.2M | $8.2M | $1.5M | $585,680 |
| Inventory | — | — | $278,000 | $111,000 | — | — | — | — | — | — |
| Total assets | $38.8M | $30.7M | $33.1M | $54.0M | $87.0M | $19.8M | $7.2M | $8.5M | $1.6M | $870,419 |
| Total liabilities | $16.5M | $37.7M | $57.1M | $43.0M | $7.6M | $20.3M | $11.9M | $11.0M | $4.5M | $1.2M |
| Shareholders' equity | $34.0M | -$7.0M | -$53.8M | $10.9M | $79.4M | $1.9M | -$4.6M | -$2.5M | -$2.8M | -$319,067 |
Growth · year-over-year · Revenue CAGR -38.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -97.6% | +20.0% | +563.1% | -24.6% | — | — | — | — | — | — |
| Net income growth | -99.0% | — | — | — | — | — | — | — | — | — |
| EPS growth | -137.8% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.